000280918 001__ 280918
000280918 005__ 20250918102641.0
000280918 0247_ $$2doi$$a10.1038/s41598-025-17278-6
000280918 0247_ $$2pmid$$apmid:40883378
000280918 0247_ $$2pmc$$apmc:PMC12397390
000280918 037__ $$aDZNE-2025-01001
000280918 041__ $$aEnglish
000280918 082__ $$a600
000280918 1001_ $$aOtto, Johannes$$b0
000280918 245__ $$aAccelerometry is a valid method to distinguish between healthy and 6-OHDA-lesioned parkinsonian rats.
000280918 260__ $$a[London]$$bSpringer Nature$$c2025
000280918 3367_ $$2DRIVER$$aarticle
000280918 3367_ $$2DataCite$$aOutput Types/Journal article
000280918 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756712326_32761
000280918 3367_ $$2BibTeX$$aARTICLE
000280918 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280918 3367_ $$00$$2EndNote$$aJournal Article
000280918 520__ $$aIn Parkinson's disease (PD), continuous sensor-based evaluation of motor symptom severity, e.g., using accelerometry, has become an emerging field of interest in clinical research. Continuous symptom monitoring would also be of interest in preclinical disease models; however, such devices are far less established in animal models, most likely due to additional requirements in size, energy consumption, and impairment-free attachment. In contrast, accelerometers manufactured in micro-electro-mechanical systems (MEMS) technology are promising sensor devices, which allow for space-saving and energy-efficient monitoring of movements. In the present study, we aim to extend the state of the art by establishing wireless accelerometer measurements as a simple and energy-efficient method to distinguish between healthy rats and the 6-hydroxydopamine (6-OHDA) PD animal model. Male Wistar-Han rats were assessed either three weeks after unilateral 6-OHDA or sham lesioning within their home cages with an extracorporeal accelerometer placed in a rodent backpack for 12 h during their active phase. The data was transmitted wirelessly to a computer, preprocessed, and a statistical analysis was performed to find differences between the datasets of 6-OHDA and sham-lesioned rats. The statistical analysis showed significant differences in the variances of the magnitude of the acceleration vectors between the two classes. In conclusion, accelerometry is a valid method to distinguish between 6-OHDA-lesioned rats with unilateral dopaminergic deficiency and their healthy counterparts. The presented method represents a first step towards automated symptom severity monitoring and provides a framework to expand the application to on-implant integrated accelerometers for continuous monitoring of symptom manifestations in rodent models of neurodegenerative diseases. Future studies are required to expand accelerometry to assess symptom severity to ultimately utilize it for preclinical research on adaptive therapies.
000280918 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280918 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280918 650_7 $$2Other$$a6-hydroxydopamine
000280918 650_7 $$2Other$$aAccelerometry
000280918 650_7 $$2Other$$aBiomarkers
000280918 650_7 $$2Other$$aMEMS accelerometer
000280918 650_7 $$2Other$$aParkinson’s disease
000280918 650_7 $$08HW4YBZ748$$2NLM Chemicals$$aOxidopamine
000280918 650_2 $$2MeSH$$aAnimals
000280918 650_2 $$2MeSH$$aAccelerometry: methods
000280918 650_2 $$2MeSH$$aAccelerometry: instrumentation
000280918 650_2 $$2MeSH$$aOxidopamine: toxicity
000280918 650_2 $$2MeSH$$aRats
000280918 650_2 $$2MeSH$$aMale
000280918 650_2 $$2MeSH$$aDisease Models, Animal
000280918 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000280918 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000280918 650_2 $$2MeSH$$aRats, Wistar
000280918 650_2 $$2MeSH$$aWireless Technology
000280918 7001_ $$aStatz, Meike$$b1
000280918 7001_ $$aWeber, Hanna$$b2
000280918 7001_ $$aKoschay, Maximilian$$b3
000280918 7001_ $$aKober, Maria$$b4
000280918 7001_ $$aPlocksties, Franz$$b5
000280918 7001_ $$aTimmermann, Dirk$$b6
000280918 7001_ $$aHaubelt, Christian$$b7
000280918 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b8$$udzne
000280918 7001_ $$aFauser, Mareike$$b9
000280918 7001_ $$aGrützmacher, Florian$$b10
000280918 7001_ $$aSpors, Sascha$$b11
000280918 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-025-17278-6$$gVol. 15, no. 1, p. 31883$$n1$$p31883$$tScientific reports$$v15$$x2045-2322$$y2025
000280918 8564_ $$uhttps://pub.dzne.de/record/280918/files/DZNE-2025-01001.pdf$$yOpenAccess
000280918 8564_ $$uhttps://pub.dzne.de/record/280918/files/DZNE-2025-01001%20SUP.pdf
000280918 8564_ $$uhttps://pub.dzne.de/record/280918/files/DZNE-2025-01001%20SUP.pdf?subformat=pdfa$$xpdfa
000280918 8564_ $$uhttps://pub.dzne.de/record/280918/files/DZNE-2025-01001.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280918 909CO $$ooai:pub.dzne.de:280918$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000280918 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000280918 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280918 9141_ $$y2025
000280918 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-29T15:28:26Z
000280918 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-29T15:28:26Z
000280918 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280918 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2024-12-18
000280918 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000280918 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280918 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000280918 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000280918 980__ $$ajournal
000280918 980__ $$aVDB
000280918 980__ $$aUNRESTRICTED
000280918 980__ $$aI:(DE-2719)5000014
000280918 9801_ $$aFullTexts